Article
A highly specific SpCas9 variant is identified by in vivo screening in yeast.
Nature biotechnology - 1 Mar 2018
Casini Antonio, Olivieri Michele, Petris Gianluca, Montagna Claudia, Reginato Giordano, Maule Giulia, Lorenzin Francesca, Prandi Davide, Romanel Alessandro, Demichelis Francesca, Inga Alberto, Cereseto Anna
Abstract excerpt
Despite the utility of CRISPR-Cas9 nucleases for genome editing, the potential for off-target activity limits their application, especially for therapeutic purposes. We developed a yeast-based assay to identify optimized Streptococcus pyogenes Cas9 (SpCas9) variants that enables simultaneous evaluation of on- and off-target activity. We screened a library of SpCas9 variants carrying random mutations in the REC3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
